NR 546 Week 2 Exam V3 | NR 546 Advanced
Pharmacology Psychopharmacology for the
PMHNP | Actual Q&A with Rationale (NR546 Week
2 Exam) | Chamberlain University
1. Which of the following describes the mechanism of action for a full agonist at a
neurotransmitter receptor?
A. It blocks the receptor from any signal transduction.
B. It reduces the constitutive activity of the receptor below baseline.
C. It enhances the signal transduction to the maximum extent possible.
D. It partially activates the receptor while competing with endogenous ligands.
Correct Answer: C
Explanation: A full agonist mimics the endogenous neurotransmitter by binding to the
receptor and inducing a maximal biological response. This process leads to the full opening
of ion channels or the complete activation of second messenger systems. By contrast,
antagonists simply block the receptor, and inverse agonists reduce activity below the
constitutive baseline level.
2. A patient is prescribed a medication that is a potent inhibitor of CYP450 2D6. Which
antidepressant would require the most caution due to this interaction?
A. Escitalopram
B. Paroxetine
,C. Sertraline
D. Vortioxetine
Correct Answer: B
Explanation: Paroxetine is both a substrate and a potent inhibitor of the CYP2D6 enzyme,
which can lead to significant drug-drug interactions. When another 2D6 inhibitor is added,
levels of drugs metabolized by this pathway can rise to toxic levels. It is critical for the
PMHNP to monitor for serotonin syndrome or increased side effects when these pathways
are compromised.
3. What is the primary role of the Vesicular Monoamine Transporter 2 (VMAT2)?
A. Reuptake of serotonin from the synaptic cleft into the presynaptic neuron.
B. Degradation of dopamine within the synaptic cleft.
C. Packaging monoamines into synaptic vesicles for release.
D. Transporting glutamate across the blood-brain barrier.
Correct Answer: C
Explanation: VMAT2 is an integral membrane protein that transports monoamines—such
as dopamine, norepinephrine, and serotonin—from the cellular cytosol into synaptic
vesicles. This packaging is essential for protecting neurotransmitters from degradation by
enzymes like monoamine oxidase (MAO). Inhibiting VMAT2 is a therapeutic strategy used
in conditions like tardive dyskinesia to reduce dopamine release.
, 4. When a ligand binds to a G-protein-linked receptor, which of the following represents the
‘second messenger’ in the signal transduction cascade?
A. Dopamine
B. Glutamate
C. Cyclic Adenosine Monophosphate (cAMP)
D. Voltage-gated sodium channels
Correct Answer: C
Explanation: In the context of signal transduction, the neurotransmitter itself is
considered the first messenger. Once it binds to a G-protein-coupled receptor, it triggers
the production of internal molecules like cAMP, which serve as the second messenger.
These second messengers then activate protein kinases, eventually leading to changes in
gene expression or ion channel state.
5. Which pharmacological property describes the process of a drug moving from the
bloodstream into the various tissues of the body?
A. Absorption
B. Metabolism
C. Excretion
D. Distribution
Correct Answer: D
Pharmacology Psychopharmacology for the
PMHNP | Actual Q&A with Rationale (NR546 Week
2 Exam) | Chamberlain University
1. Which of the following describes the mechanism of action for a full agonist at a
neurotransmitter receptor?
A. It blocks the receptor from any signal transduction.
B. It reduces the constitutive activity of the receptor below baseline.
C. It enhances the signal transduction to the maximum extent possible.
D. It partially activates the receptor while competing with endogenous ligands.
Correct Answer: C
Explanation: A full agonist mimics the endogenous neurotransmitter by binding to the
receptor and inducing a maximal biological response. This process leads to the full opening
of ion channels or the complete activation of second messenger systems. By contrast,
antagonists simply block the receptor, and inverse agonists reduce activity below the
constitutive baseline level.
2. A patient is prescribed a medication that is a potent inhibitor of CYP450 2D6. Which
antidepressant would require the most caution due to this interaction?
A. Escitalopram
B. Paroxetine
,C. Sertraline
D. Vortioxetine
Correct Answer: B
Explanation: Paroxetine is both a substrate and a potent inhibitor of the CYP2D6 enzyme,
which can lead to significant drug-drug interactions. When another 2D6 inhibitor is added,
levels of drugs metabolized by this pathway can rise to toxic levels. It is critical for the
PMHNP to monitor for serotonin syndrome or increased side effects when these pathways
are compromised.
3. What is the primary role of the Vesicular Monoamine Transporter 2 (VMAT2)?
A. Reuptake of serotonin from the synaptic cleft into the presynaptic neuron.
B. Degradation of dopamine within the synaptic cleft.
C. Packaging monoamines into synaptic vesicles for release.
D. Transporting glutamate across the blood-brain barrier.
Correct Answer: C
Explanation: VMAT2 is an integral membrane protein that transports monoamines—such
as dopamine, norepinephrine, and serotonin—from the cellular cytosol into synaptic
vesicles. This packaging is essential for protecting neurotransmitters from degradation by
enzymes like monoamine oxidase (MAO). Inhibiting VMAT2 is a therapeutic strategy used
in conditions like tardive dyskinesia to reduce dopamine release.
, 4. When a ligand binds to a G-protein-linked receptor, which of the following represents the
‘second messenger’ in the signal transduction cascade?
A. Dopamine
B. Glutamate
C. Cyclic Adenosine Monophosphate (cAMP)
D. Voltage-gated sodium channels
Correct Answer: C
Explanation: In the context of signal transduction, the neurotransmitter itself is
considered the first messenger. Once it binds to a G-protein-coupled receptor, it triggers
the production of internal molecules like cAMP, which serve as the second messenger.
These second messengers then activate protein kinases, eventually leading to changes in
gene expression or ion channel state.
5. Which pharmacological property describes the process of a drug moving from the
bloodstream into the various tissues of the body?
A. Absorption
B. Metabolism
C. Excretion
D. Distribution
Correct Answer: D
